# Integrin α6-targeted SPECT Imaging of Breast Cancer

> **NCT04289532** · EARLY_PHASE1 · COMPLETED · sponsor: **Peking University** · enrollment: 9 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 99mTc-RWY

## Key facts

- **NCT ID:** NCT04289532
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-08
- **Primary completion:** 2019-06-01
- **Final completion:** 2019-06-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04289532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04289532, "Integrin α6-targeted SPECT Imaging of Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04289532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*